
TY  - JOUR
TI  - Poster session 2: Parkinson's Disease
JO  - Movement Disorders
JA  - Mov. Disord.
VL  - 17
IS  - S5
SN  - 0885-3185
UR  - https://doi.org/10.1002/mds.10350
DO  - doi:10.1002/mds.10350
SP  - S65
EP  - S114
PY  - 2002
ER  - 

TY  - JOUR
AU  - Chor, P.J.
AU  - Santa Cruz, D. J.
TI  - Kaposi's sarcoma
JO  - Journal of Cutaneous Pathology
VL  - 19
IS  - 1
SN  - 0303-6987
UR  - https://doi.org/10.1111/j.1600-0560.1992.tb01553.x
DO  - doi:10.1111/j.1600-0560.1992.tb01553.x
SP  - 6
EP  - 20
PY  - 1992
ER  - 

TY  - JOUR
TI  - Focused Workshop
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 24
IS  - S1
SN  - 1351-5101
UR  - https://doi.org/10.1111/ene.13370
DO  - doi:10.1111/ene.13370
SP  - 729
EP  - 756
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Rheumatic Diseases
JA  - Int J Rheum Dis
VL  - 17
IS  - s1
SN  - 1756-1841
UR  - https://doi.org/10.1111/1756-185x.12344
DO  - doi:10.1111/1756-185x.12344
SP  - 1
EP  - 133
PY  - 2014
ER  - 

TY  - JOUR
TI  - Video Presentations
JO  - International Journal of Andrology
VL  - 28
IS  - s1
SN  - 0105-6263
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_6.x
DO  - doi:10.1111/j.1365-2605.2005.00551_6.x
SP  - 130
EP  - 131
PY  - 2005
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Journal of Gastroenterology and Hepatology
JA  - J Gastroenterol Hepatol
VL  - 28
IS  - S3
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.12363_1
DO  - doi:10.1111/jgh.12363_1
SP  - 1
EP  - 22
PY  - 2013
ER  - 

TY  - JOUR
TI  - THE CARDIAC SOCIETY OF AUSTRALIA AND NEW ZEALAND
JO  - Australian and New Zealand Journal of Medicine
VL  - 17
IS  - s2
SN  - 0004-8291
UR  - https://doi.org/10.1111/j.1445-5994.1987.tb04646.x
DO  - doi:10.1111/j.1445-5994.1987.tb04646.x
SP  - 557
EP  - 599
PY  - 1987
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Colorectal Disease
JA  - Colorectal Dis
VL  - 15
IS  - s1
SN  - 1462-8910
UR  - https://doi.org/10.1111/codi.12260
DO  - doi:10.1111/codi.12260
SP  - 17
EP  - 61
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Developmental Medicine & Child Neurology
JA  - Dev Med Child Neurol
VL  - 59
IS  - S2
SN  - 0012-1622
UR  - https://doi.org/10.1111/dmcn.13456
DO  - doi:10.1111/dmcn.13456
SP  - 46
EP  - 87
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts of the 7th BOMSS Annual Scientific Meeting, 28 – 29 January 2016, City Hall, Cardiff
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 103
IS  - S2
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.10133
DO  - doi:10.1002/bjs.10133
SP  - 1
EP  - 25
PY  - 2016
ER  - 

TY  - JOUR
TI  - E-Posters, EP8
JO  - BJOG: An International Journal of Obstetrics & Gynaecology
JA  - BJOG: Int J Obstet Gy
VL  - 121
IS  - s2
SN  - 1470-0328
UR  - https://doi.org/10.1111/1471-0528.12788
DO  - doi:10.1111/1471-0528.12788
SP  - 153
EP  - 176
PY  - 2014
ER  - 

TY  - JOUR
AU  - Momper, Jeremiah D.
AU  - Karesh, Alyson
AU  - Green, Dionna J.
AU  - Hirsch, Mark
AU  - Khurana, Mona
AU  - Lee, Jinoo
AU  - Kim, Myong-Jin
AU  - Mulugeta, Yeruk
AU  - Sachs, Hari C.
AU  - Yao, Lynne
AU  - Burckart, Gilbert J.
TI  - Drug development for pediatric neurogenic bladder dysfunction: Dosing, endpoints, and study design
JO  - The Journal of Clinical Pharmacology
JA  - The Journal of Clinical Pharmacology
VL  - 54
IS  - 11
SN  - 0091-2700
UR  - https://doi.org/10.1002/jcph.345
DO  - doi:10.1002/jcph.345
SP  - 1239
EP  - 1246
KW  - neurogenic bladder
KW  - clinical trial design
KW  - pharmacokinetics
KW  - pediatric urology
PY  - 2014
AB  - Abstract Pediatric drug development is challenging when a product is studied for a pediatric disease that has a different underlying etiology and pathophysiology compared to the adult disease. Neurogenic bladder dysfunction (NBD) is such a therapeutic area with multiple unsuccessful development programs. The objective of this study was to critically evaluate clinical trial design elements that may have contributed to unsuccessful drug development programs for pediatric NBD. Trial design elements of drugs tested for pediatric NBD were identified from trials submitted to the U.S. Food and Drug Administration. Data were extracted from publically available FDA reviews and labeling and included trial design, primary endpoints, enrollment eligibilities, and pharmacokinetic data. A total of four products were identified. Although all four programs potentially provided clinically useful information, only one drug (oxybutynin) demonstrated efficacy in children with NBD. The lack of demonstrable efficacy for the remainder of the products illustrates that future trials should give careful attention to testing a range of doses, using objectively measured, clinically meaningful endpoints, and selecting clinical trial designs that are both interpretable and feasible. Compiling the drug development experience with pediatric NBD will facilitate an improved approach for future drug development for this, and perhaps other, therapeutic areas.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Transplant International
JA  - Transpl Int
VL  - 32
IS  - S4
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.13526
DO  - doi:10.1111/tri.13526
SP  - 6
EP  - 27
PY  - 2019
ER  - 

TY  - JOUR
TI  - Workshops
JO  - International Journal of Andrology
VL  - 28
IS  - s1
SN  - 0105-6263
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_2.x
DO  - doi:10.1111/j.1365-2605.2005.00551_2.x
SP  - 4
EP  - 9
PY  - 2005
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - International Journal of Andrology
VL  - 28
IS  - s1
SN  - 0105-6263
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_5.x
DO  - doi:10.1111/j.1365-2605.2005.00551_5.x
SP  - 45
EP  - 129
PY  - 2005
ER  - 

TY  - JOUR
TI  - Seoul Satellite Symposium
JO  - International Journal of Andrology
VL  - 28
IS  - s1
SN  - 0105-6263
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_7.x
DO  - doi:10.1111/j.1365-2605.2005.00551_7.x
SP  - 132
EP  - 133
PY  - 2005
ER  - 

AU  - Riviere, Jim E.
C7  - pp. 677-692
TI  - Dermatotoxicology: Computational Risk Assessment
SN  - 9780470049624
UR  - https://doi.org/10.1002/9780470145890.ch24
DO  - doi:10.1002/9780470145890.ch24
SP  - 677-692
KW  - dermatotoxicology: computational risk assessment
KW  - dermal absorption principles
KW  - dermatotoxicology - computational risk assessment
PY  - 2005
AB  - Summary This chapter contains sections titled: Introduction Model Systems Principles of Dermal Absorption Dermatotoxicity Local Skin versus Systemic Endpoints QSAR Approaches to Model Dermal Absorption Pharmacokinetic Models Conclusions References
ER  - 

TY  - JOUR
TI  - BAUS abstracts
JO  - BJU International
VL  - 95
IS  - s5
SN  - 9780470049624
UR  - https://doi.org/10.1111/j.1464-410X.2005.05544.x
DO  - doi:10.1111/j.1464-410X.2005.05544.x
SP  - 1
EP  - 104
PY  - 2005
ER  - 

TY  - JOUR
AU  - Hong, Zhanying
AU  - Fan, Guorong
AU  - Chai, Yifeng
AU  - Yin, Xueping
AU  - Wu, Yutian
TI  - Stereoselective pharmacokinetics of tetrahydropalmatine after oral administration of (−)-enantiomer and the racemate
JO  - Chirality
JA  - Chirality
VL  - 17
IS  - 5
SN  - 9780470049624
UR  - https://doi.org/10.1002/chir.20161
DO  - doi:10.1002/chir.20161
SP  - 293
EP  - 296
KW  - pharmacokinetics
KW  - chiral HPLC analysis
KW  - rac-tetrahydropalmatine
KW  - (−)-tetrahydropalmatine
KW  - THP
PY  - 2005
AB  - Abstract Tetrahydropalmatine (THP) is a biologically active ingredient isolated from a traditional Chinese herb Rhizoma corydalis (yanhusuo). THP is a racemic mixture which contains 50% of the (+) and 50% of (?) enantiomer. The (?) enantiomer accounts for most of the analgesic effects. Plasma concentrations of THP enantiomers were analyzed by chiral high-performance liquid chromatography (HPLC) on a Chiralcel OJ column with quantification by UV at 230 nm. The method was used to determine the pharmacokinetics of THP enantiomers in rats and dogs after oral administration of rac-THP or (?)-THP. The pharmacokinetic profiles of the two enantiomers after dosing with rac-THP were significantly different both in rats and dogs. The mean Cmax and AUC0?∞ values in rats were 1.93 ± 0.36 ?g/ml and 6.65 ± 2.34 ?g·h/ml for the (?) enantiomer, and 1.11 ± 0.25 ?g/ml and 2.03 ± 0.45 ?g·h/ml for the (+) enantiomer. The mean Cmax and AUC0?∞ in dogs were 1.60 ± 0.81 ?g/ml and 9.88 ± 2.58 ?g·h/ml for the (?) enantiomer, while 0.36 ± 0.21 ?g/ml and 1.22 ± 0.40 ?g·h/ml for the (+) enantiomer. rac-THP at 40 mg/kg and (?)-THP at 20 mg/kg had very similar plasma concentration?time profiles, and Cmax, AUC0?∞, and t1/2 of the (?) enantiomer in both rats and dogs, indicating that the two treatments were equivalent with respect to the pharmacokinetic properties of the (?) enantiomer. Chirality 17:293?296, 2005. ? 2005 Wiley-Liss, Inc.
ER  - 

TY  - JOUR
TI  - Symposia
JO  - International Journal of Andrology
VL  - 28
IS  - s1
SN  - 9780470049624
UR  - https://doi.org/10.1111/j.1365-2605.2005.00551_3.x
DO  - doi:10.1111/j.1365-2605.2005.00551_3.x
SP  - 10
EP  - 24
PY  - 2005
ER  - 
